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Abstract
Epithelial ovarian carcinoma is the most common cause of death among gynecologic
malignancies in the United States. In the U.S., more than 21,000 women will be diagnosed with
ovarian cancer and about 15,000 women will die of the disease this year alone. Although
migration and invasion play key roles in tumor progression, the specific molecular events leading
to dissemination of ovarian tumor cells have not been well delineated. Tight junctions are an
integral component of epithelial junction complexes, which play a vital role in maintaining
epithelial integrity and cell polarity. Disruption of tight junctions is a hallmark of epithelial
cancer development and malignant progression; specifically decreased claudin-1 expression has
been associated with progression to tumor malignancy. Herein, we investigate the mechanism by
which claudin-1 expression is regulated via activation of the TGFβ and RON tyrosine kinase
receptor signaling pathways. We propose that claudin-1 expression is regulated by the activation
of the TGFβ signaling pathway (dysregulated in ovarian carcinomas), particularly SnoN/SkiL, a
key TGFβ co-repressor. In ovarian carcinoma cells, we observed that treatment with TGFβ and
MSP1 led to a marked reduction in claudin-1 protein expression. Further, we not only noted that
siRNA targeting RON led to upregulated claudin-1 mRNA and protein expression, but similar
changes in mRNA and proteins of claudin-1 were observed with SnoN and β-catenin
knockdown. Strikingly, with β-catenin knockdown, SnoN levels were notably decreased
suggesting that β-catenin could potentially regulate SnoN expression. Collectively, our results
demonstrate that claudin-1 expression is regulated by the transcriptional regulators β-catenin and
SnoN. Since identification of novel biomarkers could be beneficial in diagnosis, prognosis and
prediction of patient outcomes, these observations regarding the cellular events underlying
regulation of claudin-1 expression are of translational potential.

iv

I.

Introduction

A. Background
I.

Ovarian Carcinoma

Epithelial ovarian cancer is the most common cause of death among gynecologic
malignancies in the United States. Each year in the U.S., more than 21,000 women are diagnosed
with ovarian cancer and about 15,000 women die of the disease (surveillance, epidemiology, and
end results (SEER) Program of the National Cancer Institute). Early stage of the disease is
associated with minimal or an absence of symptoms. Hence, most cases are diagnosed at an
advanced stage when the disease has aggressively disseminated the cells from the primary tumor.
Unfortunately, this results in poor prognosis for these patients.
Epithelial-Mesenchymal Transition (EMT)

The

specific

molecular

events

leading

to

metastases

of

ovarian tumor cells
have not been well
studied, but it is
known

that

migration

and

invasion play a key
Figure 1.1-Two mechanisms through which EMT occurs in ovarian cells are shown. Cells
undergoing EMT experience an altered morphology of the rigid, cuboidal epithelia to a more
fibroblast-like mesenchymal phenotype.

role

in

the

progression. These processes are carried out through epithelial–mesenchymal transition (EMT)
which changes the morphology of the rigid, cuboidal epithelia to a mesenchymal form. EMT is
1

initiated through the dissolution of cell–cell junctions, adherens, tight and desmosomal junctions
between adjacent epithelial cells[1]. This is followed by cytoskeleton reorganization, degradation
of basement membranes and stroma, and enhanced growth rate[1]. Dissolution of the cell
junctions may occur either as a result of the acquisition of genetic and epigenetic changes that
result in mutations of their components or through repression of their expression at the
transcriptional level [2].

II.

Dysregulated TGFβ Signaling in Ovarian Cancer

Transforming growth factor-beta (TGFβ) is a multifunctional regulatory polypeptide that
controls many aspects of cellular function such as cell proliferation, differentiation, migration,
apoptosis, adhesion, angiogenesis, immune surveillance, and survival[3]. The actions of TGFβ
are dependent on several factors such as cell type, growth conditions, and the presence of other
polypeptide growth factors. TGFβ has dual functionality: (1) as a tumor suppressor (through its
effects on proliferation and apoptosis) and (2) as a tumor promoter (through effects on migration,
invasion, angiogenesis and the immune system)[3]. During the early stages of epithelial
tumorigenesis, TGFβ inhibits tumor development and growth by inducing cell cycle arrest and
apoptosis. In late stages of tumor progression, tumor cells become resistant to growth inhibition
due to inactivation of the TGFβ signaling pathway or aberrant regulation of the cell cycle[3].
The effects of TGFβ are exerted through TGFβ type 1 (TGFβRI) and type 2 receptors
(TGFβRII)[3]. Binding of the ligand causes the formation of heterotetrameric active receptor
complexes that result in the phosphorylation of the type 1 receptor by the type 2 receptor [3]. The
functional receptor complex regulates the activation of downstream Smad-dependent and Smadindependent pathways[3]. In the Smad-dependent signaling pathway, TGFβ binds TGFβRII
2

which activates TGFβRI[3]. The activated TGFβRI then recruits and phosphorylates receptorregulated Smads (R-Smads), notably Smad2/3, which then form a complex with the Co-Smad,
Smad4[3]. This complex then translocates to the nucleus to regulate transcription of TGFβ target
genes such as cyclin-dependent kinase inhibitors (i.e. p21, involved in regulating cell
survival)[3]. Thus, the overall effect of the Smad-dependent signaling is to inhibit cell growth.
Interestingly, a mutation in

Smad-Dependent TGFβ Signaling

Smad4 leads to the loss of the
tumor suppressor function of
TGFβ[3].
To date, several genes
that antagonize the inhibitory
effect of TGFβ in ovarian
cancer have been identified
(i.e. EVI1[4], SnoN/SkiL[5],
AML1/RUNX1[6], PKCι[7]).
Among

these

TGFβ

antagonists, SnoN (which is a
member of the SKI family of
nuclear proto-oncogenes) has
been well characterized[8]. In
the nucleus, SnoN can elicit
Figure 1.2- The Smad-dependent TGFβ signaling pathway demonstrating the role of
the transcriptional co-repressor SnoN in the nucleus.

either pro-oncogenic or anti-

oncogenic activities via the following two pathways: (1) SnoN may promote epithelial cell

3

proliferation by antagonizing the growth-inhibitory activity of the TGFβ/Smad pathway, or (2)
very high levels of SnoN may trigger premature senescence via stabilization of p53 in a PMLdependent manner, respectively[8]. For this reason, SnoN has been associated with these proand anti-oncogenic activities linked to cancer progression.

III.

Recepteur d’Origine Nantais (RON) Tyrosine Kinase Signaling Pathway
Another
RON Tyrosine Kinase Signaling Pathway

signaling

pathway that is associated
with invasive cancers is that
activated

by

Recepteur

d’Origine Nantais (RON), a
receptor

tyrosine

kinase

which is a member of the
MET

proto-oncogene

family[9]. Mature RON is a
180-kDa

heterodimer

composed of a 40-kDa αchain

and

a

150-kDa

transmembrane β-chain with
intrinsic
Figure 1.3- The RON tyrosine kinase signaling pathway. When activated, GSK-3
(glycogen synthase kinase-3) phosphorylates β-Catenin, targeting it for degradation in
the proteasome.

tyrosine

kinase

activity[9]. The ligand for
RON is the macrophage-

stimulating protein (MSP1)[9]. MSP1 is 725 amino acids in length and is released by
4

hepatocytes into the blood, where it is later proteolytically modified to a form that can bind to
RON leading to activation of its tyrosine kinase activity[9]. Activation of RON by MSP1
stimulates multiple signaling pathways including PI-3 kinase, Ras, MAP kinase, DVL, GSK-3β,
Smad and β-catenin leading to induction of cell adhesion, dissociation, migration and matrix
invasion[10].

IV.

Cross-talk between RON and TGFβ Signaling Pathways to Regulate Claudin-1, a Tight
Junction Marker
Tight junctions are an integral part of epithelial junction complexes and play a vital role

in creating and maintaining epithelial integrity and cell polarity[11]. Structurally, tight junctions
are composed of proteins and lipids surrounding the lateral membrane of epithelial cells[12]. A
group of integral membrane proteins known as claudins create the backbone of tight junctions.
At present, more than 20 claudin genes have been identified[11]. Disruption of tight junctions is
a hallmark of epithelial cancer development and progression towards malignancy[13]. Altered
expression of claudins such as loss of claudin-1 expression has been shown to correlate with
increased invasiveness and malignant progression of certain epithelial cancers[14, 15].
Various mechanisms have been implicated in regulation of claudin-1 expression. In colon
cancers, Smad4 of the TGFβ pathway has been shown to repress claudin-1 transcription through
modulation of β-catenin/T-cell factor/ lymphocyte enhancer factor activities[16]. Hence, there is
an inverse relationship between the expression of claudin-1, a metastasis-promoting protein, and
Smad4, a tumor suppressor protein, in colon cancer cell lines. With respect to the RON pathway,
studies with Madin-Darby Canine Kidney (MDCK) cells have shown that activation of RON
decreases E-cadherin and claudin-1 expression. Additionally, Snail and Slug, of the Snail family
5

of transcription factors, have been implicated as transcriptional repressors of claudin-1 in MDCK
cells[17]. It has further been indicated that activation of Erk1/2 signaling cascades is the first step
required for RON to exert the inhibitory effect on claudin-1 expression[17]. Ligand-dependent
RON activation disrupts tight junctions and impairs their functions via diminished claudin-1
expression[17]. Hence, activation of RON has a fundamental impact on integrity and function of
epithelial cell–cell junctions. Alterations of these cellular structures are vital in RON-mediated
tumorigenic activities leading to malignant progression.
Previous studies have shown increased expression of RON tyrosine kinase in pancreatic
tissues with Smad4 deletions in comparison to normal Smad4 expressing pancreatic cancer
specimens[18]. This indicates that the Smad-dependent TGFβ signaling pathway is critically
involved in transcriptional regulation of RON tyrosine kinase. Further studies have shown that
that RON and TGFβ can interact collaboratively including induction of EMT[13]. Recent studies
have also shown that TGFβ transcriptional mediators, EVI1 and RUNX1[4, 6], are associated
with Smad and act as transcriptional co-repressors of RON tyrosine kinase [Shafiq and
Nanjundan, unpublished results].

6

B. Preliminary Data
The cell line highlighted in red, BxPC-3, are Pancreatic Adenocarcinoma cells.

In

response to MSP1, activation of the RON tyrosine kinase has been reported. The protein
expression profiling results show that expression of RON, β-Catenin, and claudin-1 are
correlated

Cell Line Profile

positively

in

BxPC-3 cells. The
cell

line

highlighted

in

blue, SKOV3, are
ovarian

cancer

cells that can be
activated by the
MSP1
Figure 1.4- Cell line profile produced by Western analysis showing protein expression levels of various
proteins. Study primarily focused on the cell lines highlighted in the figure.

The

receptor.
protein
expression

profiling results show that RON, claudin-1 and Smad2/3 expression are highly correlated with
SKOV3 cells. The cell line highlighted in green, HEY, are human ovarian carcinoma cells. The
protein expression profiling results show that expression of β-catenin, claudin-1 and Smad2/3 are
positively correlated in HEY cells. The cell line highlighted in yellow, H358, are squamous lung
carcinoma cells that can be activated by the MSP1 receptor. The protein expression profiling
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results show that expression of RON, β-catenin, and Smad2/3 are positively correlated in H358
cells.
C. Objectives and Hypotheses
Tight junctions are an integral component of epithelial junction complexes and play a
vital role in creating and maintaining epithelial integrity and cell polarity. Disruption of tight
junctions is a hallmark of epithelial cancer development and malignant progression. The loss of
claudin-1 expression has been shown to be correlated with increased invasiveness and malignant
progression of certain epithelial cancers[14, 15]. Various mechanisms have been implicated in
regulation of claudin-1 expression including regulators of the TGFβ and RON Tyrosine Kinase
pathways. As stated in the Background, studies with colon cancers have shown that Smad4, a coSmad involved in the TGFβ pathway, represses claudin-1 expression. Furthermore, studies in
breast cancer and MDCK cells show that RON activation disrupts tight junctions and impairs
their functions through diminished claudin-1 expression[17]. Hence, activation of RON has a
fundamental impact on integrity and function of epithelial cell–cell junctions and alterations of
these cellular structures are vital components in RON-mediated tumorigenic activities that assist
malignant progression.
Undeniably, other mechanisms play a role in regulation of claudin-1 expression in cancer
cell migration and invasion. Thus, we hypothesize that claudin-1 expression is regulated by the
activation of the transforming growth factor beta signaling pathway, particularly through
SnoN/SkiL, a key TGFβ co-repressor[5]. Scientific evidence suggests that there is cross-talk
between the TGFβ pathway and receptor tyrosine kinases such as RON which is aberrantly
expressed in invasive carcinomas[9, 11]. The goal of the proposed studies is to delineate the

8

signaling pathways that are involved in regulating the expression of this tight junction protein
whose expression is dysregulated. Thus, the specific aims are as follows:
Specific Aim #1: We will test the hypothesis that altered expression of RON tyrosine kinase
leads to dysregulated claudin-1 expression
Our goal is to determine whether knockdown of RON using siRNA (targeting wild type
Ron Tyrosine Kinase) leads to altered claudin-1 expression via up/downregulated expression of
TGFβ signaling mediators including Smad2/3, SnoN, and β-catenin.
Specific Aim #2: We will test the hypothesis that cellular treatment with TGFβ and MSP1 leads
to altered expression levels of Claudin-1
Our goal is to investigate the changes in claudin-1 expression via cellular activation with
TGFβ and MSP1 ligands which activate the TGFβ receptor and RON tyrosine kinase receptor,
respectively.
Specific Aim #3: We will test the hypothesis that knockdown of β-catenin and SnoN upregulates
claudin-1 expression
Our goal is to investigate the claudin-1 expression following cellular treatment with
siRNA targeting β-catenin and SnoN in ovarian carcinoma cells.

The disruption of tight junctions is a hallmark of epithelial cancer development and
malignant progression wherein decreased claudin-1 expression is involved in this progression to
malignancy. Since identification of novel biomarkers could be beneficial in diagnosis, prognosis
and prediction of patient outcomes, it is of great importance to elucidate the detailed cellular
events underlying claudin-1 expression.

9

II.
1.

General Methods

Cell Culture
H358 Bronchial Alveolar Carcinoma and BxPC-3 Pancreatic Adenocarcinoma
cell lines were obtained from ATCC while the HEY Ovarian Carcinoma and SKOV3
Ovarian Carcinoma cell lines were kindly provided by Dr. Mills (MD Anderson Cancer
Center, Houston Texas). All four cells lines were maintained in RPMI 1640 containing 8%
Fetal Bovine Serum and 1% penicillin-streptomycin in a 5% CO2 humidified incubator at
37°C.

2.

Cell Passage
For experiments, cells were utilized at passage numbers below 30. Cells
maintained in flasks were removed from the CO2 incubator. Media was first removed from
the flasks followed by the addition of trypsin. To aid cell detachment, the flasks were gently
tapped followed by the addition of complete media. The cell-media solution was then
collected into aliquot tubes and centrifuged at 1,000rpm for 5 minutes which resulted in a
pellet fraction that was retained while the supernatant was discarded. The pellet was
resuspended in an appropriate volume of complete media and 1/5th was then plated into new
flasks.

3.

Cell Seeding and treatment with TGFβ and MSP1
H358, BxPC-3, SKOV3 and HEY cells were seeded at 250,000 cells per well in
6-well plates. Twenty-four hours post seeding, cells were treated with TGFβ (50pM), MSP1
(10ng/mL), and a combination of these two ligands (50pM TGFβ and 10ng/mL MSP1),
across the following time courses: a) 1 minute, 5 minutes, 1 hour, 3 hours and 6 hours (short
10

time course) and b) 24 hours, 48 hours, 72 hours and 96 hours (long term time course).
Immediately upon completion of these treatments, samples were placed on ice to terminate
cellular activities.
4.

Cell Seeding and treatment for siRNA
H358, BxPC-3, SKOV3 and HEY cells were seeded at 250,000 cells per well in
6-well plates. Twenty-four hours post seeding, cells were treated either with non-targeting
siRNA (control) or RON siRNA (1X). The following day, the cells were allowed to recover
followed by another siRNA transfection (2X) to obtain a greater reduction in RON
knockdown. The following day, cells were allowed to recover followed by cellular treatment
for 24 hours with TGFβ (50pM), and MSP1 (10ng/mL). Immediately upon completion of
these treatments, samples were placed on ice to terminate cellular activities.
Additional experimentations included siRNA treatment of SKOV3 and HEY cells
with β-catenin siRNA and SnoN siRNA. Cells were similarly seeded at 250,000 cells per
well in 6-well plates and siRNA methodology was followed as described above.

5.

Protein Harvest and Quantification
a.

Protein Isolation
Media was removed from each well of 6-well plates followed by the addition of

1X Phosphate Buffer Saline (PBS). The plates were gently rocked for a few seconds and the
PBS was removed from each well. One-hundred µL of RPPA Lysis Buffer (containing a
cocktail of protease inhibitors) was added to each well and the plates were incubated on ice
for one hour. After incubation, the cells were scraped vigorously and the resulting lysate
collected into Eppendorf tubes. The samples were then centrifuged at 15,000rpm for 10
11

minutes as 4°C. Following centrifugation, the pellet was discarded while the supernatant
was retained for further analysis. Samples were kept on ice at all times to minimize protein
degradation.
b.

Bicinchoninic Acid (BCA) Assay for Total Sample Protein Concentration
Bovine Serum Albumin (BSA) standards (0, 25, 50, 100, 250, 500, 750, 1000,

2000µg/mL) and samples were pipetted in duplicate into a 96-well plate (2µL per well).
Next, BCA Reagent A and BCA Reagent B were mixed at a ratio of 9.8ml:0.2ml. Twohundred µL of the BCA Reagent mixture was added to each well containing a standard or
sample. The plate was then placed in a 37°C incubator for 30 minutes. After incubation, the
plate was read at 570nm in a BioTek Synergy 2 plate reader. The resulting data was
analyzed using a Microsoft Office Excel document to generate a standard curve and
determine the protein concentrations of the unknown samples. These samples were then
diluted to 1-2mg/mL with lysis buffer and 6X SDS sample loading buffer to prepare gel
loading sample to run of SDS-PAGE gels.
6.

SDS-PAGE Gel (Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis)
a.

Preparation of SDS-PAGE Gels
Components for preparation of lower and upper gel were mixed in two separate

50ml aliquot tubes. The quantity used of each component (NANOpure water, gel buffer
(upper or lower), 30% acrylamide, APS and TEMED) was determined by the percentage of
the gel required (i.e. 8% or 12%). The lower gel mixture was first poured into a Criterion gel
cassette. After lower gel polymerization, the upper gel was mixed, poured, and a comb was
inserted for formation of loading wells (18 wells).
b.

Running of SDS-PAGE Gels
12

Samples were boiled at 95°C for 5 minutes, vortexed for 2 seconds, and
centrifuged for 10 seconds at 15,000 rpm. The gels were placed appropriately into the
Criterion electrophoresis system. The basin of the gel cassette and the external chambers of
the gel apparatus were filled with Running Buffer. 20µl of samples and molecular weight
markers were loaded into the appropriate wells. The gels were electrophoresed for 2 hours at
100 volts.
c.

Gel Transfer to Polyvinylidine Fluoride Membrane (PVDF) Membranes Using a
Semi-Dry Transfer Method
Prior to the western blotting process, the gels were transferred to a high protein

binding membrane (PVDF). For transfer, the gel was removed from the cassette and
incubated briefly with transfer buffer. The membrane was activated by soaking for one
minute in 100% methanol followed by rinsing 3 times with NANOpure water, and
immersion in Transfer Buffer. Blotting paper was soaked in Transfer Buffer and placed on
the blotting panel of the Trans-Blot apparatus. The PVDF membrane, the gel, and another
piece of blotting paper were then placed on top of this blotting paper (in this order).
Throughout this process, care was taken to remove all bubbles from this “blot sandwich”.
The Trans-Blot apparatus was closed and the transfer was conducted for 2 hours with a
voltage limit of 20 Volts. Depending on the number of blots transferred, a constant current
of 0.11 amps (1 blot) or 0.15 amps (2 blots) was utilized.
7.

Western Blotting
a.

Incubation with Antibodies
After the gels were transferred to membranes, the membranes were washed in 1X

Tris-Buffered Saline Tween-20 (TBST) for 10 minutes on a platform rotator. Then, the
13

TBST was drained and the membrane was placed on the platform rotator for 1 hour in 1X
TBST with 5% milk for “blocking”. The milk solution was then removed and the membrane
was incubated with appropriate primary antibody on the rotator overnight at 4°C. The
membrane was washed in 1X TBST for 1 hour on the rotator with the TBST being replaced
every 15 minutes. Appropriate secondary antibody was then applied to the membrane and
incubated with shaking at room temperature for 1 hour. The membrane was then washed in
1X TBST for 1.5 hours on the rotator with the TBST being replaced every 15 minutes.
b.

Developing Western Blots
To develop western blots, the developer was turned on and warmed up at least 20

minutes in advance. Prior to use, the ECL developing reagents (HRP Luminol and Peroxide
Buffer) were mixed at a 1:1 ratio. After secondary antibody incubation and subsequent 1X
TBST washes, the membranes were completely covered with the ECL mixture and
incubated at room temperature for 5 minutes. The blots were then placed in the developing
cassette and moved to the darkroom where Kodak film was exposed to the blot and
developed.
c.

Western Blot Membrane Regeneration
Blots were regenerated after developing by washing in 1X TBST for 10 minutes

on the platform rotator. TBST was then discarded and 20 mL of restoration buffer (Pierce)
was applied to the membrane. The membrane was incubated for 1 hour at 50°C with
moderate shaking, then washed in 1X TBST for 10 minutes on the platform rotator, and then
blocked for 2 hours in 1X TBST containing 5% milk. The milk solution was discarded and
the membrane was incubated with primary antibody on the rotator overnight at 4°C.
8. RNA Isolation
14

RNA isolation was performed using the QIAGEN RNeasy Mini Kit. Forty-eight
hours post 2X siRNA transfection, cells were washed with 1ml of Dulbecco's Phosphate
Buffered Saline (DPBS). After discarding the DPBS, 350µl of RLT buffer was added to
each well. Following one minute incubation, the wells were scraped and lysates transferred
into shredder columns for homogenization.
The columns were centrifuged for 2 minutes at 14,000 rpm. 300µl of 70% ethanol
(RNA grade) was added to the eluate. After mixing, eluates were transferred into spin
columns and centrifuged for 15 seconds at 10,000 rpm. Then, the flow-through was
discarded, 700µl of RW1 buffer was added to each spin column, and centrifuged for 15
seconds at 10,000 rpm. After the flow-through was discarded again, 500µl of RPE buffer
was added to each spin column, and centrifuged for 15 seconds at 10,000 rpm. Next, the
flow-through was discarded, another 500µl of RPE buffer was added to each spin column,
and centrifuged for 2 minutes at 10,000 rpm. The spin columns were then centrifuged for 1
minute at 14,000 rpm followed by the addition of 30µl of RNase free water. This was
followed by one minute incubation and centrifugation for one minute at 10,000 rpm. The
flow-through was re-added to the spin columns followed by the addition of a further 10µl of
RNase free water and then centrifuged for one minute at 10,000 rpm. The spin columns
were then discarded and the RNA samples were transferred into appropriately labeled
Eppendorf tubes. The RNA concentration of each sample was quantified using the
NANOdrop apparatus and 20ng/µl dilutions (with total volumes of 50µl) were prepared. All
RNA samples were stored at -80°C until further use.
9. Real Time PCR

15

Real Time PCR was used to quantify the mRNA transcript levels of claudin-1
following SnoN, β-catenin, and RON knockdown using siRNA in HEY cells. β-Actin
probe/primers were used to determine the β-Actin RNA levels as an endogenous control.
For both the β-Actin control and genes of interest, master mixes were prepared using the
components provided in the Applied Biosystems OneStep RT-PCR Kit.
The master mixes were pipetted into a 96-well plate followed by the addition of
40ng of RNA. All samples were analyzed in duplicate. PCR was run using the StepOnePlus
Real-Time PCR System which was programmed as follows: (1) 48°C for 30 minutes
(reverse transcriptase reaction), (2) 95°C stage for 10 minutes, and (3) 40 cycles alternating
between 95°Cfor 15 seconds and 60°C for 1 minute. Results were analyzed using the
following formula: 2-ΔΔCT. ΔCT= CT value of gene of interest minus CT value of β-Actin.
ΔΔCT= ΔCT minus ΔCT of CT of siRNA sample.
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III.

Results
Part

1:

RON

Knockdown

Leads to Upregulated Claudin1 Protein Levels
In Aim #1, we tested the
hypothesis

that

dysregulated

RON tyrosine kinase expression
leads to altered claudin-1 protein
levels. In high RON Tyrosine
Figure 3.1- Western analysis of RON knockdown in SKOV3, H358, and BxPC-3
cells. Cells were seeded at 250,000 cells per well in 6-well plates. Twenty-four
hours post seeding, cells were treated either with non-targeting siRNA (control)
or RON siRNA (1X). The following day, the cells were allowed to recover followed
by another siRNA transfection (2X). Protein was harvested, quantified, and run
on SDS-PAGE. Following the transfer of gels to PVDF membranes, Western
blotting was performed using antibodies targeting (1) RON, (2) SnoN, (3) claudin1, (4) β-catenin, (5) Smad2/3, and (6) GAPDH used as the loading control.

were

Kinase expressing BxPC-3, H358
and SKOV3 cell lines, the effects
of RON knockdown using siRNA

investigated

(results shown in Figure
3.1). Western blotting
was

performed

to

examine the expression
of

TGFβ

signaling

mediators (Smad2/3 and
SnoN) as well as βCatenin.
knockdown

RON
led

to

Figure 3.2- Western analysis of RON knockdown in HEY cells. Cells were seeded at 250,000
cells per well and at 24 hours post seeding, were either treated with non-targeting siRNA
(control) or RON siRNA (1X). Another siRNA transfection (2X) was performed the following
day to obtain a greater reduction in RON knockdown. Protein was then harvested, quantified,
run on SDS-PAGE, and transferred to PVDF membranes. Western blotting was performed
using antibodies targeting (1) RON, (2) SnoN, (3) claudin-1, (4) β-catenin, (5) Smad2/3, and
(6) GAPDH used as a loading control.

greater than 80% reduction in RON protein expression in all three cell lines. Coincident with
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decreased Ron levels, we observed that, (1) claudin-1 protein levels were increased in both
SKOV3 and H358 cell lines, (2) β-catenin protein levels were increased in SKOV3 cells slight
increase in SnoN expression in SKOV3 cells.
To further validate these changes in an independent cell line, we selected HEY cells, a
highly metastatic ovarian cancer cell line (see Figure 3.2). Similar to SKOV3 and H358 cells
(Figure 3.1), we observed that claudin-1 protein levels were increased with RON knockdown in
HEY cells. Furthermore, similar to SKOV3 cells (Figure 3.1), β-catenin protein levels were
increased with RON knockdown in HEY cells. However, SnoN expression levels appear to be
unchanged in HEY cells in contrast to SKOV3 cells.

Part 2: Reduction of Claudin-1 Protein Expression Upon Cellular Treatment with TGFβ
and MSP1
The goal of Aim #2 was to investigate changes in claudin-1 protein expression following
cellular activation with TGFβ and MSP1 ligands which activate the TGFβ receptor and RON

Figure 3.3-Effects of MSP1 and TGFβ on ERK activation (pERK1/2) in H358, BxPC-3, and SKOV3 cells. Cells
were seeded at 250,000 cells per well and twenty-four hours post seeding, cells were treated with TGFβ (50pM)
and MSP1 (10ng/mL) across the following time course: 1 minute, 5 minutes, 1 hour, 3 hours and 6 hours (short
time course). Western blotting was performed using antibodies targeting (1) pERK1/2 and (6) GAPDH used as a
loading control.

tyrosine kinase receptor, respectively. The effects of MSP1 and TGFβ activation on claudin-1
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expression were investigated across a series of short (up to 6 hours) and long (up to 96 hours)
time course treatments. In the short-term time course, Western blotting was performed to
examine the activation of pERK1/2 (also known as MAPK), as shown in Figure 3.3. We
observed a marked activation of MAP kinase at 3 hours post treatment in BxPC-3 cells, 1 hour
post treatment in H358 cells and 5 minutes post treatment in SKOV3 cells. This was detected
using an antibody against MAP kinase which specifically detects its phosphorylation status.

Figure 3.4- Effects of long term cellular treatments with MSP1 and TGFβ treatment H358, BxPC-3, and SKOV3 cells.
Cells were seeded at 250,000 cells per well in 6-well plates. Twenty-four hours post seeding, cells were treated with TGFβ
(50pM), MSP1 (10ng/mL), across the following time course: 24 hours, 48 hours, 72 hours, and 96 hours. Protein was
harvested, quantified, separated by SDS-PAGE, and transferred to PVDF membranes. Western blotting was then
performed using antibodies targeting (1) claudin-1, (2) β-catenin, (3) Smad2/3, (4) SnoN, and (4) GAPDH used as the
loading control.

In the long-term time course, expression levels of claudin-1, β-catenin, Smad2/3, and
SnoN were investigated up to 96 hours post MSP1 and TGFβ addition. As shown in Figure 3.4,
we observed decreased claudin-1 expression 24 hour post treatment with MSP1 and TGFβ in
both BxPC-3 and H358 cells. Furthermore, we observed decreased claudin-1 expression 24 to 96
hours post TGFβ treatment in SKOV3 cells. β-catenin protein levels were increased 24 hours
post treatment with both MSP1 and TGFβ in SKOV3 cells. SnoN expression levels were
increased 24 hours post treatment with combinatorial treatment of both MSP1 and TGFβ in
SKOV3 cells. In contrast, we did not detect any marked changes in Smad2/3 expression.
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Figure 3.5 shows the
western analysis of short and
long-term time courses of
combinatorial treatments of
both MSP1 and TGFβ. Since
the main focus of this study is
Figure 3.5- Combinatorial short and long-time course cellular treatment with MSP1
and TGFβ in SKOV3 cells. Cells were seeded at 250,000 cells per well and twenty-four
hours post seeding, cells were treated with TGFβ (50pM) and MSP-1 (10ng/mL), or a
combination of these two ligands (50pM TGFβ with 10ng/mL MSP1) either at 5
minutes (short time course, STC) or at 24 hours (long time course, LTC). Cell lysates
were harvested, protein quantified, separated by SDS-PAGE, and transferred to PVDF
membrane. Western blotting was using antibodies detecting (1) pERK1/2, (2) β-catenin,
(3) claudin-1, and (4) GAPDH as the loading control.

ovarian

carcinomas,

we

selected SKOV3 cells to
examine

the

effects

of

combinatorial treatments of

these two ligands at 24 hours posttreatment. MAP kinase activation
(via detection of phosphorylated
ERK1/2) is observed in short time
course TGFβ treatment but not in
combination treatment with both
MSP1 and TGFβ. In the long time
course, activation of MAP kinase
decreased with both MSP1 and
TGFβ but more dramatically upon
combination of both of these two

Figure 3.6- Long time course treatment of MSP1 and TGFβ in HEY cells. Cells
were seeded at 250,000 cells per well and twenty-four hours post seeding, cells
were treated with TGFβ (50pM), and MSP-1 (10ng/mL), across the following
time course: 24 hours, 48 hours, 72 hours and 96 hours. Protein was then
harvested, quantified, separated by SDS-PAGE, and transferred to PVDF
membranes. Western blotting was performed using antibodies detecting (1) βcatenin, (2) claudin-1, (3) Smad2/3, (4) SnoN, and (5) GAPDH as a loading
control.

ligands. Consistent with our previous observations, claudin-1 expression levels decreased with
only MSP1 or TGFβ alone; however, the reduction in claudin-1 was more marked when cells
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were treated with both TGFβ and MSP1. In contrast to these dramatic changes in claudin-1
protein levels, β-catenin expression levels were unchanged.
To further validate these observations and determine whether these results can be
generalizable to other carcinoma cell lines, we repeated these studies using HEY cells. Figure 3.6
displays the Western analysis of the long time course while Figure 3.7 displays the Western
analysis of the combination treatments of MSP1 and TGFβ for two selected time points (i.e. 24
and 48 hours). In the long term time course in HEY cells (Figure 3.6), claudin-1 expression
levels decreased 24 hours post treatment with MSP1 and TGFβ. Smad2/3 expression levels
decreased 48 hours post treatment with TGFβ while no changes were seen in SnoN or β-catenin
expression levels. In the combination study
(shown in Figure 3.7), we observed a marked
reduction in claudin-1 expression following
24 hours post treatment with MSP1, TGFβ,
and the combination of these two ligands. In
contrast, the protein expression levels of
Smad2/3 were increased 24 hours post
treatment with MSP1, TGFβ, and the
Figure 3.7- Long time course treatment of MSP1, TGFβ and the
combination of the two ligands in HEY cells. Cells were seeded
at 250,000 cells per well and twenty-four hours post seeding,
cells were treated with TGFβ (50pM) and MSP-1 (10ng/mL),
and a combination of these two ligands (50pM TGFβ and
10ng/mL MSP-1) at 24 and 48 hours. This was followed by
protein harvesting, quantification, separation by SDS-PAGE,
and transferred to PVDF membranes. Western blotting was
performed using antibodies detecting (1) SnoN, (2) claudin-1, (3)
β-catenin,(4) Smad2/3, and (5) GAPDH as a loading control.

combination of these two ligands. SnoN
expression levels were slightly increased post
24 and 48 hours treatment of MSP1, TGFβ,
with a more marked increase with the

combinatorial treatment at 48 hours post treatment. Similarly, β-catenin protein expression levels
were increased at 24 and 48 hour post treatment with TGFβ.
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Part 3: SnoN and β-Catenin Knockdown Leads to Upregulated Claudin-1 Protein Levels
Aim #3 of this study was to test the hypothesis that knockdown of β-catenin and SnoN
upregulates

claudin-1

expression.

Initially,

SKOV3 cells were used
to

Figure 3.8- Effects of β-catenin knockdown in SKOV3 cells. Cells were seeded at 250,000 cells
per well in 6-well plates. Twenty-four hours post seeding, cells were treated either with nontargeting siRNA (control) or β-catenin siRNA (1X). The following day, the cells were allowed to
recover followed by another siRNA transfection (2X). Protein was harvested, quantified with
BCA, and run on SDS-PAGE. Following the transfer of gels to PVDF membranes, Western
blotting was performed using antibodies detecting (1) β-catenin, (2) SnoN, (3) claudin-1, and (4)
GAPDH as a loading control.

investigate

the

claudin-1

expression

following

cellular

treatment with siRNA
targeting

β-catenin.

However, SKOV3 cells
(as shown in Figure 3.8)
were

extremely

slow

growing and thus, the
protein amounts were
suboptimal for further
analyses. Hence, HEY
cells were used since
they

yielded

an

abundance of protein for
Western

analyses.

Figure 3.9- Effects of β-catenin knockdown in HEY cells. Cells were seeded at 250,000 cells
per well in 6-well plates. Twenty-four hours post seeding, cells were treated either with nontargeting siRNA (control) or SnoN siRNA (1X), or β-catenin siRNA (1X). The following day,
the cells were allowed to recover followed by another siRNA transfection (2X). The following
day, cells were allowed to recover followed by cellular treatment for 24 hours with TGFβ
(50pM), MSP1 (10ng/mL), and a combination of the two ligands (50pM TGFβ and 10ng/mL
MSP1). Protein was harvested, quantified, and run on SDS-PAGE. Following the transfer of
gels to PVDF membranes, Western blotting was performed using antibodies detecting (1)
SnoN, (2) β-catenin, (3) claudin-1, (4) Smad2/3, and (5) GAPDH as a loading control.

Additional studies included siRNA treatment of HEY cells with β-catenin siRNA and SnoN
siRNA, as noted in Figure 3.9. With β-catenin siRNA, the combination treatment of MSP1 and
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TGFβ led to increased claudin-1 expression compared to β-catenin siRNA cells treated with only
MSP1 or TGFβ. SnoN expression decreased in cells treated with β-catenin siRNA. Smad2/3
expression is decreased with MSP1, with a further marked decrease upon TGFβ treatment as
well as with the combination of MSP1 and TGFβ. An even more dramatic reduction in protein
levels was observed with Smad3 in contrast to Smad2.

Part 4: RON, SnoN, and β-Catenin Knockdown Leads to Upregulated Claudin-1 mRNA
Levels
To

Table 3.1- RNA concentrations and purity of samples.

Sample ID
Control siRNA-1
Control siRNA-2
RON siRNA-1
RON siRNA-2
SnoN siRNA-1
SnoN siRNA-2
β-Catenin siRNA-1
β-Catenin siRNA-2

ng/µl
855.03
966.05
1061.38
1063.95
842.19
661.59
1187.45
715.44

λ260
21.376
24.151
26.535
26.599
21.055
16.54
29.686
17.886

λ280
10.372
11.73
12.854
12.885
10.18
8.024
14.429
8.71

260/ 280
2.06
2.06
2.06
2.06
2.07
2.06
2.06
2.05

validate

the

results we obtained in the
above sections where we
examined protein levels,
we

performed

analysis

to

RNA

determine

whether these changes occurred at the
transcriptional

level.

HEY

cells

were

transfected with control, SnoN, β-catenin, and
RON siRNA. RNA was then isolated and
quantified

(A260/A280=2.0).

The

RNA

concentrations for these samples are presented
in Table 3.1. The RNA concentrations for all

Figure 3.10 – PCR Amplification Plot of RNA levels of SnoN,
claudin-1, and RON in siRNA treated HEY cells.

samples were standardized to 20ng/μl and
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qPCR (quantitative PCR) was then performed using probes specific to claudin-1, SnoN, and
RON mRNA transcripts.

β-Actin probes/primers were used as an endogenous control.

Table 3.3 – Raw Data and Calculation of CT values from qPCR.
Probe

Sample

CT

ΔCT

ΔΔCT

2^-ΔΔCT

Claudin-1

Control
siRNA-1

32.72

9.48

0

1

Claudin-1

Control
siRNA-2

32.87

9.58

0.096

0.935

SnoN
siRNA-1

31.99

Claudin-1

SnoN
siRNA-2

31.98

9.34

-0.139

1.101

Claudin-1

β-Catenin
siRNA-1
β-Catenin
siRNA-2

31.78

8.91

-0.575

1.490

31.52

8.58

-0.904

1.871

Claudin-1

RON
siRNA-1

31.71

8.71

-0.772

1.708

Claudin-1

RON
siRNA-2

31.79

8.79

-0.693

1.617

SnoN

Control
siRNA-1
Control
siRNA-2

28.29

5.057

0

1

28.25

4.952

-0.104

SnoN
siRNA-1
SnoN
siRNA-2

29.42

6.648

29.37

6.731

β-Catenin
siRNA-1
β-Catenin
siRNA-2

28.16

5.282

0.226

0.855

28.19

5.248

0.192

0.876

SnoN

RON
siRNA-1

28.20

5.195

0.138

0.909

SnoN

RON
siRNA-2
Control
siRNA-1
Control
siRNA-2

28.31

5.309

0.252

0.840

33.93

10.70

0

1

34.20

10.909

0.212

0.863

RON

SnoN
siRNA-1

34.02

11.242

0.544

0.686

RON

SnoN
siRNA-2
β-Catenin
siRNA-1
β-Catenin
siRNA-2

33.95

11.309

0.612

0.654

34.69

11.816

1.119

0.461

34.91

11.964

1.266

0.416

RON
siRNA-1
RON
siRNA-2

34.82

11.818

1.121

0.459

34.61

11.603

0.906

0.534

Claudin-1

Claudin-1

SnoN
SnoN
SnoN
SnoN
SnoN

RON
RON

RON
RON
RON
RON

Table 3.2- Averaged β-actin CT Values.
Probe

Sample
Control siRNA-1

β-Actin

9.22

-0.266

1.203

Cт
23.23

Control siRNA-2

β-Actin

23.29

SnoN siRNA-1

β-Actin

22.78

SnoN siRNA-2

β-Actin

22.63

β-Catenin siRNA-1

β-Actin

22.88

β-Catenin siRNA-2

β-Actin

22.95

RON siRNA-1

β-Actin

23.00

RON siRNA-2

β-Actin

23.00

Table 3.4 - Average and SD of Data.
Probe

Sample

Mean

Standard
Deviation

1.075

Claudin-1

Control
siRNA

0.967

0.046

1.591

0.332

Claudin-1

1.152

0.072

1.674

0.313

SnoN
siRNA

Claudin-1

β-Catenin
siRNA

1.681

0.270

Claudin-1

RON
siRNA

1.662

0.064

SnoN

Control
siRNA

1.038

0.053

SnoN

SnoN
siRNA

0.323

0.013

SnoN

β-Catenin
siRNA

0.865

0.014

SnoN

RON
siRNA

0.874

0.049

RON

Control
siRNA

0.932

0.097

RON

SnoN
siRNA

0.670

0.022

RON

β-Catenin
siRNA

0.438

0.032

RON

RON
siRNA

0.497

0.052
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The PCR study yielded an Amplification Plot (Figure 3.10) from which CT (Threshold
Cycle) values were obtained. Table 3.2 shows β-Actin CT values. We performed comparative
qPCR analysis where we subtracted the CT value of β-actin from the CT value of claudin-1. This
was similarly performed for the other genes of interest whose transcript levels were quantified.
This resulted in a ΔCT value. ΔΔCT was calculated by normalizing samples to a reference
sample. For example, Control-1 would be subtracted from SnoN-1 to obtain the ΔΔCT for SnoN.
To determine the RNA-fold change, the following equation was used: 2-ΔΔCT. Sample

Figure 3.11 – Relative mRNA transcript levels of (A) claudin-1, (B) SnoN, and (C) RON resulting from SnoN, β-catenin,
and RON siRNA transfection in HEY cells.

calculations are shown in Table 3.3. Finally, the resulting values for each sample were averaged
and standard deviations were derived (Tables 3.4).
These data were then graphed (Figure 3.11). The knockdown of SnoN, β-catenin, and
RON led to an increase in the abundance of claudin-1 mRNA transcripts (Figure 3.11a).
However, this increase is observed most markedly with β-catenin and RON siRNA than SnoN
siRNA. Additionally, β-catenin and RON knockdown resulted in a decrease in the abundance of
SnoN mRNA transcripts (Figure 3.11b). Interestingly, SnoN and β-catenin knockdown resulted
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in a marked decrease in RON transcript levels (Figure 3.11c). Furthermore, the reduction is
greater with β-catenin siRNA than with SnoN siRNA.
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IV.

Discussion

Tight junction proteins such as claudin-1 are an integral component of epithelial junction
complexes and play a vital role in maintaining epithelial integrity and cell polarity. Disruption of
tight junctions is a hallmark of epithelial cancer development and malignant progression. The
loss of claudin-1 expression has been shown to be correlated with increased invasiveness and
malignant progression of certain epithelial cancers[14, 15]. Herein, we investigated whether
claudin-1 expression is regulated by activation of mediators in the TGFβ signaling pathway,
particularly SnoN/SkiL, a key TGFβ co-repressor, in ovarian cancer cells. This hypothesis was
investigated through three specific aims: (1) to determine whether altered expression of RON
tyrosine kinase leads to dysregulated claudin-1 expression; (2) to determine whether cellular
treatment with TGFβ and MSP1 leads to altered expression levels of claudin-1; and (3) to
determine whether knockdown of β-catenin and SnoN upregulates claudin-1 expression.
In Figure 3.1 and 3.2, we observed that claudin-1 protein levels were increased with RON
knockdown in HEY and SKOV3 cells, respectively. Similarly, as reported in breast cancer and
MDCK cells, RON activation disrupts tight junctions and impairs their functions through
reduced claudin-1 expression[17]. Interestingly, we also noted that β-catenin and SnoN levels
were slightly increased in both SKOV3 and HEY cells. We propose that these changes may be
independent of the effect of RON knockdown on claudin-1 levels since increased SnoN levels
are expected to counter the effects of reduced RON expression. However, we did not observe
these effects in two independent cell lines, H358 and BxPC-3 cells, suggesting that these effects
are likely unique to ovarian carcinoma cells.
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In Figure 3.3, we investigated the immediate changes in the activation status of certain
cascades following RON and TGFβRII/I receptor activation. We primarily focused on the MAP
kinase signaling cascade since it is known to be a major player in numerous signaling pathways
and modulates β-catenin activity[19-22]. Cells treated with MSP1 and TGFβ led to a marked
phosphorylation of pERK1/2. We also noted that TGFβ is more potent in altering claudin-1
levels in contrast to MSP1. In addition, long-term treatments (Figure 3.4 and 3.5) of these cells
with these ligands led to marked reduction of claudin-1 levels. Thus, we propose that these
changes in expression of these tight junction proteins may be due to the activation of the MAP
kinase signaling cascade. We have observed an increase in SnoN levels and further, the inverse
relationship between claudin-1 expression levels and SnoN supports the data presented in Figure
3.9. Undeniably, disruption of tight junctions is indeed a hallmark of cancer development as
noted in various cancer subtypes including colon cancer and as our work has potentially shown,
in ovarian cancer development.
We observed that siRNA targeting RON tyrosine kinase led to a marked elevation in
claudin-1 protein. As shown in Figure 3.11, the changes that we observed in protein expression
also occurred at the RNA level. This indicates that claudin-1 is regulated at the transcriptional
level and since SnoN is a transcriptional co-repressor, this could be a potential pathway by which
claudin-1 levels are modulated. The mechanism by which this could potentially occur is shown
in Figure 4.1. Various mechanisms have been implicated in regulation of claudin-1 expression
including regulators of the TGFβ and RON Tyrosine Kinase pathways. Studies with colon
cancers have shown that Smad4, a co-Smad, involved in the TGFβ pathway represses claudin-1
expression[18]. Activation of kinase linked receptors (i.e. RON and TGFβRII/I) normally occur
following ligand binding (i.e MSP1 or TGFβ) followed by activation of intricate intracellular
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signaling cascades (including MAP kinase activation, Figure 3.3) which leads to the progressive
movement of the signal into the nuclear compartment. Within the nucleus, the activity of
transcriptional co-repressors and co-activators modulate transcriptional induction. Both β-catenin
and SnoN are mediators in such intracellular signaling pathways.
One mechanism of β-catenin activation involves GSK3 (glycogen synthase kinase 3)
which phosphorylates β-catenin and targets the protein for proteasome mediated degradation[1922]. Thus, dephosphorylated β-catenin will promote its cytoplasmic and thus, nuclear
accumulation where it could potentially modulate the transcription of target genes such as
claudin-1[19-22]. On the other hand, SnoN is regulated by phosphorylation via TAK1 which
promotes its ubiquitination via E3 ubiquitin ligase and eventually determines the quantity of
SnoN protein that is present[23]. Interestingly, we also noted that β-catenin and SnoN altered
claudin-1 protein levels. These changes were observed at the RNA levels implicating
transcriptional regulation of claudin-1.
With knockdown of SnoN and β-catenin, changes were observed in claudin-1 expression
independent of the presence of ligand or receptor activation. With β-catenin knockdown, SnoN
levels were reproducibly decreased suggesting that β-catenin may regulate SnoN expression
either 1) directly via protein-protein interaction (via C-terminal binding protein which has been
reported to interact in a complex with both SnoN and β-catenin) or 2) potentially indirectly via
modulation of SnoN transcription as a β-catenin target gene. Strikingly, we noted that the
morphology of the β-catenin knockdown HEY cells were more epithelial-like and polarized
(results not shown). This observation is consistent with the role of claudin-1 in maintaining cell
polarity in cell-cell interactions. This was not observed in RON or SnoN knockdown in cells; this
indicates that there are some other critical components which aid or promote cell polarity such as
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zonula occludens (ZO-1), gap junctions, and/or desmosomes. It is presently unknown whether
the signaling mechanism by which β-catenin alters claudin-1 levels is through alteration in
activities of SnoN transcription co-repressor activities.
Future

RON and TGFβ Transcriptional regulation of Claudin-1 Expression

will

studies

investigate

the

effects of a MAP kinase
inhibitor (PD98059) as
well as other pathways
including the PI3K/AKT,
p38, and JNK pathways
to further identify the
signaling

pathways

leading to modulation of
claudin-1
levels.

transcript
Thus,

elucidation

further
of

the

detailed signaling events
Figure 4.1-Proposed mechanism of claudin-1 regulation via SnoN demonstrating potential
cross-talk between the TGFβ signaling pathway and RON tyrosine kinase.

underlying regulation of

claudin-1 expression will certainly be invaluable in future studies to identify novel biomarkers in
ovarian cancer detection and treatment.
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